NEW YORK–(BUSINESS WIRE)–BTIG announced today that it will host the “BTIG Biotechnology Conference” on Monday, August 12th in New York. The conference will feature several of the industry’s key opinion leaders and other panelists from emerging and established biotechnology companies. Hosted by BTIG Biotechnology Analysts Robert “Bert” Hazlett, Amanda Murphy, CFA, and Thomas Shrader, PhD, CFA, the conference will include one-on-one meetings and in-depth panel discussions.
BTIG’s private conference is open to its institutional investor clients and will cover topical issues which impact biotechnology companies and healthcare today. Discussion topics include treatment for sickle cell disease; solid and liquid tumors; TTR amyloidosis; lipids; central nervous system therapeutics; and targeted oncology.
“Our biotech team has attracted some of the industry’s most renowned thought leaders and corporate management teams to participate in our upcoming conference,” commented David Lenchus, Director of Research at BTIG. “We look forward to producing this thematic event, where we will bring together key public and private biopharmaceutical companies with some of the most sophisticated and active institutional investors.”
BTIG’s Corporate Access program hosts client events across the consumer, energy, financials, healthcare, real estate, shipping and technology, media and telecommunications sectors.
For more information about the conference, email email@example.com. Please note that participants must be pre-registered to attend.
To access BTIG insights, contact a BTIG representative or visit www.btigresearch.com.
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 600 employees, BTIG, LLC and its affiliates operate out of 18 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.